Shots:
- Siolta Therapeutics has entered into a preclinical research partnership with Cowellnex, a joint investment of Kirin and Kyowa Kirin, to develop an LBP focused on preventing necrotizing enterocolitis (NEC)
- The collaboration will utilize Siolta’s Precision Symbiotics Platform, enabling Cowellnex to expedite the discovery and development of innovative product aimed at preventing the occurrence of NEC
- Precision Symbiotics Platform helps in microbiome data analysis, machine learning, anaerobic microbiology, and translational studies for developing innovative products
Ref: Businesswire | Image: Siolta Therapeutics
Related News:- Neurocrine Biosciences and Takeda Amend Partnership to Develop and Commercialize Osavampator in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
